Working… Menu

A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01076699
Recruitment Status : Suspended (recruiting/enrolling participants has halted prematurely but potentially will resume Oct)
First Posted : February 26, 2010
Last Update Posted : July 19, 2010
Information provided by:
Revogenex, Inc.

Brief Summary:
The purpose of this study is to determine if RVX-100 is safe and effective in treating acute abdominal pain in patients with irritable bowel syndrome accompanied by diarrhea.

Condition or disease Intervention/treatment Phase
Irritable Bowel Syndrome Drug: 0.075 mg RVX-100 Drug: 0.125 mg RVX-100 Drug: 0.250 mg RVX-100 Drug: placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 192 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Four-Arm Trial to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo for the Treatment of Abdominal Pain in Patients With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)
Study Start Date : March 2010
Estimated Primary Completion Date : December 2010
Estimated Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Group taking 0.075 mg RVX-100
This group is taking 0.075 mg RVX-100
Drug: 0.075 mg RVX-100
This group is taking the lowest dose of RVX-100

Active Comparator: Group taking 0.125 mg RVX-100
This group is taking 0.125 mg RVX-100
Drug: 0.125 mg RVX-100
This group is taking an average dose of RVX-100

Active Comparator: 0.250 mg RVX-100
This group is taking 0.250 mg RVX-100
Drug: 0.250 mg RVX-100
This group is taking the highest dose of RVX-100

Placebo Comparator: placebo
This group is taking a placebo
Drug: placebo
This group is taking a placebo
Other Name: Sugar pill

Primary Outcome Measures :
  1. Change in weekly average abdominal pain severity score from baseline. [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Change in weekly average Abdominal Pain Severity score from baseline to week 8 [ Time Frame: 8 weeks ]
  2. Time to response, based on abdominal pain severity scores. [ Time Frame: 8 weeks ]
  3. Proportion of subjects in each treatment arm who are weekly responders. [ Time Frame: 8 weeks ]
  4. Proportion of subjects in each treatment arm who are end-of-treatment responders [ Time Frame: 8 weeks ]
  5. Number of pain-free days per week, based on responses to the Abdominal Pain Severity scale [ Time Frame: 8 weeks ]
  6. Bowel urgency [ Time Frame: 8 weeks ]
  7. Stool consistency [ Time Frame: 8 weeks ]
  8. Stool frequency [ Time Frame: 8 weeks ]
  9. Fecal incontinence [ Time Frame: 8 weeks ]
  10. Bloating [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Adult male or female, aged ≥18 and ≤75 years old.
  • Subject/ legal representative is able to understand and sign informed consent form.
  • Have abdominal pain severity defined as weekly average of "worst abdominal pain in past 24 hours" score of ≥ 3.0 on a 0 to 10 point scale during the second week of the Baseline phase.
  • Have IBS-D according to Rome III criteria and ≥25% of stools on the BSS inclusion criteria rated as 6 or 7 during the Baseline phase.
  • Not pregnant, lactating, or breastfeeding.
  • If a female of childbearing potential, the subject must agree to remain abstinent or practice two medically acceptable forms of contraception during the screening, baseline, treatment, and withdrawal periods. Acceptable forms of contraception include oral contraception, intrauterine devices, implantable devices, and barrier methods. If a barrier method is chosen, a double barrier is required.
  • Discontinue all medications used to treat IBS symptoms (prescription and non-prescription) and prescription analgesics at least two (2) weeks prior to the start of the baseline period until after the final study visit. (Final study visit occurs two (2) weeks after the last dose of study medication.) Acetaminophen may be used as a rescue medication as long as it is carefully documented on the Case Report Form (CRF). Fiber supplements are permitted if they are taken at the same frequency and amount throughout the study and were taken during the four (4) weeks prior to the Baseline phase. This must be documented in the source document file and the CRF.
  • Willing and able to comply with all study-related procedures, including not incorporating significant changes in diet.

Exclusion Criteria:

  • Positive for fecal ova and parasites (O&P) or Clostridium difficile (ELISA) or other bacterial pathogens (standard stool culture) during the Screening phase.
  • Taking medication for the treatment of IBS during the baseline phase (other than acetaminophen).
  • Taking any treatment for IBS including any of the following classes of medications within 2 weeks prior to baseline visit (Visit 2), or at any point during the study:

    • Antispasmodic or anticholinergic agents
    • Combination products including atropine, hyoscyamine, phenobarbital, and/or scopolamine
    • Antidepressants (such as monoamine oxidase inhibitors [MAOI], selective serotonin reuptake inhibitors [SSRIs], and tricyclic antidepressants), to include, but not limited to the following:
    • Combination products including pheniramine, phenyltoloxamine, or pyrilamine
    • Laxatives
    • Opioids/narcotic analgesics
    • Phenothiazines antipsychotics and anti-emetics
  • History of anticholinergic psychosis (psychosis associated with exposure to anticholinergic medications).
  • Laboratory values greater than three times the upper limit of normal (ULN) alanine transaminase (ALT/SGPT) or aspartate transaminase (AST/SGOT).
  • Laboratory values greater than two times the ULN for total bilirubin (TBil), creatinine (sCr) or blood urea nitrogen (BUN).
  • Active infection with hepatitis (A, B, or C) or positive confirmatory test for HIV1, or HIV2 (results of the HIV testing will be kept strictly confidential. Subject may wish to undergo HIV testing as per the guidelines for HIV testing requirements in India pursuant to NACO).
  • History of allergic reaction to l-hyoscyamine or atropine, or any component in the formulation of the study drugs.
  • Evidence of disease (based on medical history) that could adversely affect the subject's safety during participation in this study or interfere with the interpretation of study results, including but not limited to: glaucoma; pyloric stenosis; clinically significant benign prostatic hypertrophy; clinically significant heart or lung or disease; active peptic ulcer; celiac disease; digestive tract obstruction or paralysis; myasthenia gravis; inflammatory bowel disease; poorly controlled hypertension; hyperthyroidism; decreased hepatic or renal function; urinary retention, or lactose intolerance.
  • Use of any investigational drug within 30 days prior to the Baseline Visit (Visit 2), or anytime during study.
  • History of non-compliance with treatment or clinical visit attendance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01076699

Layout table for location information
United States, Maryland
Metropolitan Gastroenterology Group
Chevy Chase, Maryland, United States, 20815
Sponsors and Collaborators
Revogenex, Inc.
Layout table for investigator information
Principal Investigator: Robert Hardi, M.D., CPI Metropolitan Gastroenterology Group PC, Chevy Chase Clinical Research
Layout table for additonal information
Responsible Party: George Kottayil, Chief Operations Officer, Revogenex Identifier: NCT01076699    
Other Study ID Numbers: RVG-09-005
First Posted: February 26, 2010    Key Record Dates
Last Update Posted: July 19, 2010
Last Verified: July 2010
Keywords provided by Revogenex, Inc.:
abdominal pain
irritable bowel
Additional relevant MeSH terms:
Layout table for MeSH terms
Irritable Bowel Syndrome
Pathologic Processes
Signs and Symptoms, Digestive
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases